Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study
Tania Jain,Noel Estrada-Merly,M. Queralt Salas,Soyoung Kim,Jakob D DeVos,Min Chen,Xi Fang,Rajat Kumar,Marcio Andrade-Campos,Hany Elmariah,Vaibhav Agrawal,Mahmoud Aljurf,Ulrike Bacher,Talha Badar,Sherif M Badawy,Karen Kuhn Ballen,Amer Beitinjaneh,Vijaya R. Bhatt,Christopher N Bredeson,Zachariah DeFilipp,Bhagirathbhai Dholaria,Nosha Farhadfar,Shatha Farhan,Arpita Gandhi,Siddhartha Ganguly,Usama Gergis,Michael R. Grunwald,Nada Hamad,Betty K. Hamilton,Yoshihiro Inamoto,Madiha Iqbal,Omer Jamy,Mark Juckett,Mohamed A Kharfan-Dabaja,Maxwell M Krem,Deepesh P Lad,Jane L Liesveld,Monzr M. Al Malki,Adriana K. Malone,Hemant S. Murthy,Guillermo Ortí,Sagar S. Patel,Attaphol Pawarode,Miguel-Angel Perales,Marjolein W.M van der Poel,Olle Ringden,David A Rizzieri,Alicia Rovo,Bipin N Savani,Mary Lynn Savoie,Sachiko Seo,Melhem M Solh,Celalettin Ustun,Leo F. Verdonck,John R Wingard,Baldeep Wirk,Nelli Bejanyan,Richard J Jones,Taiga Nishihori,Betul Oran,Ryotaro Nakamura,Bart L Scott,Wael Saber,Vikas Gupta
DOI: https://doi.org/10.1182/bloodadvances.2024013451
IF: 7.642
2024-06-25
Blood Advances
Abstract:We aim to evaluate impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using CIBMTR registry data for HCTs done between 2013 and 2019. In all 1597 undergoing HCT for myelofibrosis, the use of haploidentical donors increased from 3% in 2013 to 19% in 2019. In study eligible, 1032 patients who received peripheral blood grafts for chronic phase myelofibrosis, 38% recipients of haploidentical-HCT were of non-White/Caucasian ethnicity. Matched sibling donor (MSD)-HCTs were independently associated with superior overall survival (OS) in the first 3 months [reference MSD, haploidentical HR 5.80 (95% CI 2.52-13.35), matched unrelated HR 4.50 (95% CI 2.24-9.03), and mismatched unrelated HR 5.13 (95% CI 1.44-18.31), P<0.001]. This difference in OS aligns with lower graft failure with MSD [haploidentical HR 6.11 (95%CI 2.98-12.54), matched unrelated HR 2.33 (95%CI 1.20-4.51), mismatched unrelated HR 1.82 (95%CI 0.58-5.72). There was no significant difference in OS among haploidentical, matched unrelated, and mismatched unrelated donor HCTs in the first 3 months. Donor type was not associated with differences in OS beyond 3 months post-HCT, relapse, disease-free survival or OS among patients who underwent HCT within 24 months of diagnosis. Patients who experienced graft failure had more advanced disease and commonly used nonmyeloablative conditioning. While MSDs remain a superior donor option due to improved engraftment, there is no significant difference in HCT outcomes from haploidentical and matched unrelated donors. These results establish haploidentical-HCT with posttransplantation cyclophosphamide as a viable option in myelofibrosis, especially for ethnic minorities underrepresented in the donor registries.
hematology